Pfizer and BioNTech Secure Victory Over CureVac in Patent Battle

Pfizer and BioNTech successfully invalidated two CureVac patents at London's High Court. The lawsuit filed in September 2022 focused on patents related to mRNA technology, essential for their COVID-19 vaccine.

In a significant legal victory, Pfizer and its German collaborator BioNTech have successfully invalidated two patents held by rival CureVac at London's High Court. This development marks a critical win for the pharmaceutical giants as it pertains to patented mRNA technology, a cornerstone of their COVID-19 vaccine production.

The lawsuit was initiated in September 2022, when Pfizer and BioNTech challenged the validity of CureVac's patents that they viewed as infringing upon the foundations of their innovative mRNA technology. This technology is pivotal in creating the mRNA strands that spearheaded the development of their effective COVID-19 vaccines.

The outcome of this case underscores the ongoing and competitive race in patent rights and technology advancements among the pharmaceutical industry leaders, with implications likely to ripple through the sector, impacting future innovations and patents.

(With inputs from agencies.)